Clinical Trials Logo

Pancreatic Cancer clinical trials

View clinical trials related to Pancreatic Cancer.

Filter by:

NCT ID: NCT00547612 Completed - Pancreatic Cancer Clinical Trials

Positron Emission Tomography Using [18F]-Labeled Substance P Antagonist Receptor Quantifier in Finding Disease in Patients With Pancreatic Cancer

Start date: September 2007
Phase: Phase 1
Study type: Interventional

RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) using [18F]-labeled substance P antagonist receptor quantifier, may be effective in finding disease in patients with pancreatic cancer. PURPOSE: This phase I trial is studying how well a PET scan using [18F]-labeled substance P antagonist receptor quantifier works in finding disease in patients with pancreatic cancer.

NCT ID: NCT00547144 Completed - Pancreatic Cancer Clinical Trials

Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer

Start date: October 2005
Phase: Phase 1
Study type: Interventional

To determine the safety, feasibility and appropriate dendritic cell dose to vaccinate patients with pancreas cancer

NCT ID: NCT00544193 Completed - Pancreatic Cancer Clinical Trials

Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer

Start date: December 1997
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of gemcitabine when given together with radiation therapy in treating patients with locally advanced upper gastrointestinal cancer.

NCT ID: NCT00540579 Completed - Pancreatic Cancer Clinical Trials

CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas

Start date: November 2007
Phase: Phase 1/Phase 2
Study type: Interventional

Because the activity of CC-4047 addresses numerous mechanisms of carcinoma growth inhibition - including, but not limited to anti-angiogenesis - CC-4047 has been selected for development as part of induction chemotherapy regimens for solid tumors. This study in pancreatic cancer is designed to determine the appropriate CC-4047 dose and regimen in combination with gemcitabine.

NCT ID: NCT00536614 Completed - Pancreatic Cancer Clinical Trials

Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer

SPaCe-01
Start date: May 2005
Phase: Phase 2
Study type: Interventional

This is multicenter, open-label, randomized, phase II trial in patients with locally advanced or metastatic pancreatic cancer. Primary objective: objective response rate. Secondary objectives: safety, time to disease progression, median duration of response, time to treatment failure, overall survival time, correlation between bio-pathological characterization (EGFR, akt, MAPks) objective response and survival

NCT ID: NCT00534001 Completed - Lung Cancer Clinical Trials

Bupropion in Helping Adults Stop Smoking

Start date: January 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Bupropion may help people stop smoking by decreasing the symptoms of nicotine withdrawal. Giving bupropion over a longer period of time may be effective in helping people stop smoking. PURPOSE: This randomized phase II trial is studying how well bupropion works in helping adults stop smoking.

NCT ID: NCT00529984 Completed - Breast Cancer Clinical Trials

A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies

CEA(6D)VRP
Start date: September 2007
Phase: Phase 1/Phase 2
Study type: Interventional

STUDY OBJECTIVES 1. The primary objective of this protocol is to determine the safety of immunization with CEA(6D) VRP in patients with advanced or metastatic CEA expressing malignancies. 2. The secondary objectives are to evaluate CEA-specific immune response to the immunizations and obtain preliminary data on response rate.

NCT ID: NCT00521404 Completed - Pancreatic Cancer Clinical Trials

Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer

Start date: August 15, 2007
Phase: Phase 2
Study type: Interventional

Phase 2 study to determine the efficacy and safety of CS-1008 when given with gemcitabine to subjects with previously untreated and unresectable (unable to be surgically removed) or metastatic (spread to other areas beyond the pancreas) pancreatic cancer.

NCT ID: NCT00514163 Completed - Pancreatic Cancer Clinical Trials

GEM vs GEM+TS-1 for Advanced Pancreatic Cancer

Start date: June 2007
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to compare tumor response rate of the test arm(gemcitabine+S-1) with the control arm(gemcitabine alone) in patients with unresectable pancreatic cancer

NCT ID: NCT00511264 Completed - Pancreatic Cancer Clinical Trials

Laparoscopic Ultrasound Guided Tissue Sampling in Patients With Cancer of the Upper Gastrointestinal Tract

Start date: May 2007
Phase: N/A
Study type: Observational

Laparoscopic Ultrasound (LUS) is an important part of the pre-treatment evaluation of patients with upper gastrointestinal tract cancer (esophageal, gastric, pancreatic and liver cancer). When a suspect lesion is visualized during LUS a biopsy should be provided in order to differentiate between benign and malignant lesions. A new system for LUS guided biopsy has been developed, but how often these biopsies are clinically relevant (i.e. changing patient management)and how reliable are these biopsies are unknown. The study hypothesis is that LUS guided biopsies are accurate and clinically relevant in the pre-treatment evaluation of patients with upper gastrointestinal tract cancer.